Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Carmell Therapeutics (CTCX) is now available.
Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepping down as CEO, to be succeeded by Kendra Bracken-Ferguson, effective July 30, 2024. Bracken-Ferguson, a seasoned professional in the digital media and beauty industries, will bring her extensive experience from founding BrainTrust and developing over 200 influencer-driven brands to her new role. Alongside a base salary of $300,000, her compensation includes performance-based bonuses and equity awards, with additional severance benefits outlined in her executive employment agreement.
See more data about CTCX stock on TipRanks’ Stock Analysis page.